| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Process | STA Standard |
| ID number | 1596 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 24 July 2023 | Please note that following on from advice received from the company, timelines for this appraisal are still to be confirmed. Further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes. |
| 16 January 2020 | The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly. Please note that following on from advice received from the company the timelines for this appraisal are to be confirmed. As this appraisal has been referred, NICE will continue to monitor any developments and will provide an update as and when the situation changes. |
| 27 June 2019 | As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly. Please note that following on from advice received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late January 2020. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust evidence submission |
| 17 May 2019 - 17 June 2019 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 09 May 2019 | In progress. Referred 29 April 2019 |
For further information on our processes and methods, please see our CHTE processes and methods manual